發(fā)布時(shí)間：2018-05-31 02:32

  本文選題：GEO + 上皮性卵巢癌��； 參考：《暨南大學(xué)》2017年博士論文

【摘要】：第一章FBXW7在上皮性卵巢癌和正常卵巢上皮細(xì)胞中的表達(dá)分析目的:明確FBXW7在上皮性卵巢癌組織和正常卵巢上皮組織中的表達(dá)情況方法:(1)依托隸屬于NCBI(美國(guó)國(guó)立衛(wèi)生研究院)的GEO(Gene Expression Omnibus,基因表達(dá)數(shù)據(jù)庫),以“上皮性卵巢癌”為關(guān)鍵字搜索出編號(hào)為GDS3592上皮性卵巢癌表達(dá)譜,然后用其檢測(cè)數(shù)據(jù)中FBXW7的表達(dá)情況。在數(shù)據(jù)庫中再利用Affymetrix 2.0芯片對(duì)12例人正常卵巢上皮細(xì)胞和12例人卵巢癌上皮細(xì)胞中的表達(dá)譜情況進(jìn)行了分析。抽取FBXW7在正常人卵巢上皮細(xì)胞和卵巢癌上皮細(xì)胞中的表達(dá)數(shù)值,進(jìn)而進(jìn)行統(tǒng)計(jì)學(xué)分析。(2)培養(yǎng)包括A2780cp、A2780s、SKOV3和CAOV3上皮性卵巢癌細(xì)胞以及正常卵巢上皮細(xì)胞HOEC。(3)收集細(xì)胞總蛋白和總m RNA,利用WB和real-time PCR檢測(cè)FBXW7基因在蛋白和m RNA水平上的表達(dá)情況。結(jié)果:(1)FBXW7在12例正常人卵巢上皮細(xì)胞中的表達(dá)值為907.0±76.36;FBXW7在12例人卵巢癌上皮細(xì)胞中的表達(dá)值為599.9±54.31;FBXW7在正常人卵巢上皮細(xì)胞中的表達(dá)情況顯著高于上皮性卵巢癌上皮細(xì)胞中的表達(dá)情況。(2)于蛋白水平上FBXW7在正常卵巢上皮細(xì)胞HOEC中高表達(dá);在A2780cp、SKOV3和CAOV3細(xì)胞中無表達(dá);在A2780s細(xì)胞中低表達(dá)。(3)于m RNA水平上,相比于卵巢上皮細(xì)胞HOEC,FBXW7在A2780cp、A2780s、SKOV3和CAOV3細(xì)胞中均處于低表達(dá)的情況。結(jié)論:FBXW7在正常人卵巢上皮細(xì)胞中的表達(dá)顯著高于上皮性卵巢癌上皮細(xì)胞中的表達(dá)第二章體外細(xì)胞實(shí)驗(yàn)研究FBXW7對(duì)上皮性卵巢癌細(xì)胞生長(zhǎng)的作用及機(jī)理目的:研究FBXW7對(duì)上皮性卵巢癌細(xì)胞生長(zhǎng)作用的影響方法:(1)構(gòu)建pc DNA3.1載體介導(dǎo)的人FBXW7過表達(dá)質(zhì)粒,然后用于轉(zhuǎn)染A2780cp和A2780s細(xì)胞,用WB方法檢測(cè)蛋白水平的FBXW7的表達(dá)。(2)利用CCK8實(shí)驗(yàn)檢測(cè)細(xì)胞增殖情況、利用克隆形成實(shí)驗(yàn)檢測(cè)細(xì)胞克隆形成能力。(3)PI染色結(jié)合流式分析對(duì)p-FBXW7質(zhì)粒轉(zhuǎn)染組和對(duì)照質(zhì)粒轉(zhuǎn)染組上皮性卵巢癌細(xì)胞的周期分布情況進(jìn)行檢測(cè)。(4)利用WB對(duì)p-FBXW7質(zhì)粒轉(zhuǎn)染后經(jīng)嘌呤霉素篩選得到的p-FBXW7質(zhì)粒穩(wěn)定過表達(dá)組和對(duì)照組細(xì)胞中凋亡相關(guān)蛋白的表達(dá)情況進(jìn)行檢測(cè)。(5)利用WB對(duì)FBXW7過表達(dá)上皮性卵巢癌細(xì)胞和對(duì)照組細(xì)胞中凋亡相關(guān)蛋白Bcl-2、Bax、Bcl-x L、Caspase-3和周期相關(guān)蛋白Cyclin B1、Cyclin D1和Cyclin E1的表達(dá)情況進(jìn)行檢測(cè),進(jìn)而明確FBXW7調(diào)控上皮性卵巢癌細(xì)胞生物學(xué)特性的分子機(jī)制。結(jié)果:(1)過表達(dá)FBXW7能顯著抑制A2780cp及A2780s細(xì)胞細(xì)胞的增殖,其抑制率分別為56.2%及58.7%。(2)過表達(dá)FBXW7能顯著抑制A2780cp及A2780s細(xì)胞的克隆形成,對(duì)克隆形成的抑制率分別為75.6%及77.3%。(3)過表達(dá)FBXW7顯著促進(jìn)A2780cp細(xì)胞凋亡的發(fā)生(Ctrl組細(xì)胞的凋亡率為:3.9±0.6%;FBXW7過表達(dá)組細(xì)胞的凋亡率為13.4±0.9%);過表達(dá)FBXW7顯著促進(jìn)A2780s細(xì)胞凋亡的發(fā)生(Ctrl組細(xì)胞的凋亡率為:4.1±0.49%;FBXW7過表達(dá)組細(xì)胞的凋亡率為14.8±2.2%)。(4)過表達(dá)FBXW7有效將A2780cp細(xì)胞阻滯在G1期(Ctrl組細(xì)胞的G1期細(xì)胞率為:46.7±6.5%;FBXW7過表達(dá)組細(xì)胞的G1期細(xì)胞率為68.3±7.3%);2)過表達(dá)FBXW7有效將A2780s細(xì)胞阻滯在G1期(Ctrl組細(xì)胞的G1期細(xì)胞率為:52.1±3.8%;FBXW7過表達(dá)組細(xì)胞的G1期細(xì)胞率為70.1±8.2%);(5)在A2780cp和A2780s細(xì)胞中過表達(dá)FBXW7能顯著誘導(dǎo)凋亡促進(jìn)蛋白Bax和Caspase 3的表達(dá)并且能顯著下調(diào)凋亡抑制蛋白Bcl-2和Bcl-x L的表達(dá)。抑制周期檢查點(diǎn)蛋白Cyclin E1和Cyclin D1的表達(dá),但對(duì)Cyclin B1的表達(dá)無顯著的調(diào)控作用。結(jié)論:過表達(dá)FBXW7能顯著抑制上皮性卵巢癌細(xì)胞的增殖、克隆形成,促進(jìn)凋亡的發(fā)生。同時(shí),過表達(dá)FBXW7能有效將上皮性卵巢癌細(xì)胞阻滯在G1期,抑制細(xì)胞周期進(jìn)行。對(duì)以上凋亡促進(jìn)蛋白及抑制蛋白的研究結(jié)果提示在上皮性卵巢癌細(xì)胞中過表達(dá)FBXW7調(diào)控了線粒體依賴的凋亡發(fā)生途徑。第三章動(dòng)物實(shí)驗(yàn)研究FBXW7對(duì)上皮性卵巢癌皮下移植瘤生長(zhǎng)的作用及機(jī)理研究目的:從動(dòng)物實(shí)驗(yàn)層面上研究FBXW7對(duì)上皮性卵巢癌皮下移植瘤生長(zhǎng)的作用及機(jī)理方法:將所篩選得到的FBXW7穩(wěn)定過表達(dá)A2780cp細(xì)胞和對(duì)照組細(xì)胞接種到裸鼠右腹側(cè)皮下,建立皮下移植瘤。(1)繪制腫瘤生長(zhǎng)曲線,進(jìn)而明確FBXW7對(duì)上皮性卵巢癌皮下移植瘤生長(zhǎng)的調(diào)控作用。(2)石蠟包埋和切片后利用免疫組化染色檢測(cè)FBXW7的表達(dá)情況,明確FBXW7在上皮性卵巢癌皮下移植瘤組織中高表達(dá)。(3)利用免疫組化染色檢測(cè)增殖相關(guān)指標(biāo)PCNA和腫瘤血管生成相關(guān)指標(biāo)CD31的表達(dá)情況;(4)利用TUNEL檢測(cè)腫瘤組織中細(xì)胞凋亡情況。結(jié)果:(1)過表達(dá)FBXW7能顯著抑制A2780cp皮下移植瘤生長(zhǎng),對(duì)腫瘤體積的抑制率為70.6%(Ctrl組腫瘤體積為:1463.2±175.3mm3;FBXW7組腫瘤體積為:432.5±65.3mm3);對(duì)腫瘤重量的抑制率為69.5%(Ctrl組腫瘤體積為:1.38±0.21g;FBXW7組腫瘤體積為:0.42±0.08g)。(2)在p-FBXW7質(zhì)粒穩(wěn)定轉(zhuǎn)染組的皮下移植瘤組織中FBXW7顯著高表達(dá);p-FBXW7質(zhì)粒穩(wěn)定轉(zhuǎn)染組的皮下移植瘤組織中FBXW7的陽性率為62.3±4.8%。(3)在A2780cp的Ctrl組與FBXW7組相比,其皮下移植瘤組織中處于增殖期的細(xì)胞數(shù)分別為為70.2±8.2%及18.3±4.2%。(4)比較A2780cp的Ctrl組及p-FBXW7組皮下移植瘤組織中處于凋亡的細(xì)胞分別為5.3±1.5%及24.3±4.4%。(5)在Ctrl組A2780cp皮下移植瘤組織中血管密度為43.8±8.7;在FBXW7組A2780cp皮下移植瘤組織中血管密度為8.4±3.2。結(jié)論:過表達(dá)FBXW7抑制A2780cp皮下移植瘤生長(zhǎng),顯著抑制腫瘤細(xì)胞的增殖活性促進(jìn)細(xì)胞凋亡的發(fā)生并且能顯著抑制腫瘤血管生成。
[Abstract]:The expression of FBXW7 in epithelial ovarian cancer and normal ovarian epithelial cells was analyzed in Chapter 1: to identify the expression of FBXW7 in epithelial ovarian cancer and normal ovarian epithelial tissue: (1) relying on the GEO (Gene Expression Omnibus, gene expression database) belonging to NCBI (National Institutes of health of the United States), "epithelial" Ovarian cancer "searched the expression profile of GDS3592 epithelial ovarian cancer for the keyword, and then used it to detect the expression of FBXW7 in the data. In the database, the expression profiles of 12 normal ovarian epithelial cells and 12 human ovarian cancer epithelial cells were analyzed by Affymetrix 2 chip. The FBXW7 was extracted in normal human eggs. A2780cp, A2780s, SKOV3 and CAOV3 epithelial ovarian cancer cells, and normal ovarian epithelial cells HOEC. (3) collected the total cell protein and total m RNA, and the WB and real-time PCR were used to detect the table of FBXW7 gene at the level of protein and M. (2) Results: (1) the expression of FBXW7 in 12 normal human ovarian epithelial cells was 907 + 76.36, and the expression of FBXW7 in the epithelial cells of 12 human ovarian cancer cells was 599.9 + 54.31. The expression of FBXW7 in normal human ovarian epithelial cells was significantly higher than that in epithelial ovarian carcinoma. (2) FBXW7 at protein level. High expression in normal ovarian epithelial cells HOEC; no expression in A2780cp, SKOV3 and CAOV3 cells; low expression in A2780s cells. (3) at m RNA level, compared to HOEC in ovarian epithelial cells, FBXW7 is low in A2780cp, A2780s, SKOV3, and cells. Conclusion: expression in normal human ovarian epithelial cells Expression in epithelial ovarian cancer epithelial cells second chapters in vitro study on the effect and mechanism of FBXW7 on the growth of epithelial ovarian cancer cells: the study of the effect of FBXW7 on the growth of epithelial ovarian cancer cells: (1) construction of human FBXW7 overexpressed plasmid mediated by PC DNA3.1 vector, and then used to transfect A2780cp and A 2780s cells were used to detect the expression of FBXW7 at the protein level by WB. (2) the cell proliferation was detected by CCK8 test and the clone formation test was used to detect the cell clone formation ability. (3) PI staining combined flow analysis was used to detect the periodic distribution of epithelial ovarian cancer cells in the p-FBXW7 plasmid transfected group and the control plasmid transfected group (4). WB was used to detect the expression of apoptosis related proteins in the p-FBXW7 plasmid stable overexpression group and the control group after transfection of the p-FBXW7 plasmid. (5) the apoptosis related egg white Bcl-2, Bax, Bcl-x L, Caspase-3 and cycle related eggs of FBXW7 overexpressed epithelial ovarian cancer cells and control group cells were used by WB. The expression of white Cyclin B1, Cyclin D1 and Cyclin E1 was detected, and the molecular mechanism of FBXW7 regulating the biological characteristics of epithelial ovarian cancer cells was identified. Results: (1) over expression of FBXW7 could significantly inhibit the proliferation of A2780cp and A2780s cell cells, and the inhibition rates were 56.2% and 58.7%. (2), respectively. The inhibition rates of s cells were 75.6% and 77.3%. (3), respectively. The expression of FBXW7 significantly promoted the apoptosis of A2780cp cells (the apoptosis rate of Ctrl group was 3.9 + 0.6%; the apoptosis rate of FBXW7 overexpressed group was 13.4 + 0.9%); overexpression of FBXW7 significantly promoted the apoptosis of A2780s cells (the apoptotic rate of Ctrl group cells) It was 4.1 + 0.49%; the apoptosis rate of FBXW7 overexpression group was 14.8 + 2.2%. (4) overexpression of FBXW7 effectively blocked A2780cp cells at G1 stage (the G1 stage rate of Ctrl group cells was 46.7 + 6.5%, the G1 stage cell rate of FBXW7 overexpression group was 68.3 + 7.3%); 2) FBXW7 effectively blocked A2780s cells in G1 phase (Ctrl group cells) The rate of FBXW7 was 52.1 + 3.8%; the cell rate of G1 cells in the overexpression group was 70.1 + 8.2%. (5) the overexpression of FBXW7 in A2780cp and A2780s cells could significantly induce the expression of apoptosis promoting protein Bax and Caspase 3, and significantly downregulated the expression of apoptosis inhibitor Bcl-2 and Bcl-x L. But the expression of Cyclin B1 has no significant regulatory effect. Conclusion: overexpression of FBXW7 can significantly inhibit the proliferation of epithelial ovarian cancer cells, clone and promote the occurrence of apoptosis. At the same time, overexpression of FBXW7 can effectively block epithelial ovarian cancer cells in G1 stage and inhibit cell cycle. The results suggest that overexpression of FBXW7 in epithelial ovarian cancer cells regulates the apoptotic pathway of mitochondrial dependence. The third chapter studies the effect and mechanism of FBXW7 on the growth of epithelial ovarian cancer subcutaneous xenografts: the effect of FBXW7 on the growth of subcutaneous xenografts of the epithelial ovarian cancer from the animal experimental level. The mechanism method: the selected FBXW7 stable overexpression A2780cp cells and the control group cells were inoculated into the right ventral subcutaneous of the nude mice to establish subcutaneous transplantation tumor. (1) the tumor growth curve was plotted, and then the regulation of FBXW7 on the growth of the epithelial ovarian cancer subcutaneous transplanted tumor was determined. (2) the paraffin embedding and sectioning were used to detect F by immunohistochemical staining. The expression of BXW7 showed high expression of FBXW7 in the subcutaneous tissue of epithelial ovarian cancer. (3) the expression of proliferation related index PCNA and tumor angiogenesis related index CD31 were detected by immunohistochemical staining; (4) the cell apoptosis in tumor tissues was detected by TUNEL. Results: (1) overexpression of FBXW7 could significantly inhibit the A2780cp skin. The growth inhibition rate of tumor growth was 70.6% (group Ctrl tumor volume was 1463.2 + 175.3mm3; FBXW7 group tumor volume was 432.5 + 65.3mm3); the tumor weight inhibition rate was 69.5% (Ctrl group tumor volume was 1.38 + 0.21g; FBXW7 group tumor volume was 0.42 + 0.08g). (2) in the subcutaneous transplantation group of the stable transfection group of p-FBXW7 plasmid The positive rate of FBXW7 in the tissue of the p-FBXW7 plasmids stable transfection group was 62.3 + 4.8%. (3) in the Ctrl group of A2780cp and the FBXW7 group. The number of cells in the proliferation stage of the subcutaneous tumor tissue was 70.2 + 8.2% and 18.3 + 4.2%. (4) in Ctrl and p-FBXW7 subcutaneous xenografts. The apoptotic cells in the tissue were 5.3 + 1.5% and 24.3 + 4.4%. (5) in the Ctrl group A2780cp subcutaneous tumor tissue, the vascular density was 43.8 + 8.7, and the vascular density in the A2780cp subcutaneous tissue of group FBXW7 was 8.4 + 3.2. conclusion: overexpression of FBXW7 inhibits the growth of the subcutaneous transplantation tumor of A2780cp and significantly inhibits the proliferation activity of the tumor cells. Apoptosis can significantly inhibit tumor angiogenesis.
【學(xué)位授予單位】：暨南大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.31

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 高國(guó)蘭,牛曉宇,張崇淑,彭芝蘭;40歲以下婦女上皮性卵巢癌的臨床及病理特點(diǎn)[J];實(shí)用癌癥雜志;2000年03期

2 管先華,謝瑞夢(mèng),趙曉虹,田昌英;上皮性卵巢癌遠(yuǎn)處轉(zhuǎn)移15例分析[J];四川腫瘤防治;2001年01期

3 王常玉,顧美皎,王世宣,馬丁;三種化療方案治療晚期上皮性卵巢癌的療效比較[J];實(shí)用婦產(chǎn)科雜志;2002年04期

4 李雙弟,萬小平,楊兆瑞,胡宏慧,席曉薇,徐先明;血管內(nèi)皮生長(zhǎng)因子及其受體與上皮性卵巢癌發(fā)展[J];腫瘤;2003年03期

5 袁令芹;上皮性卵巢癌226例臨床病理分析[J];腫瘤防治雜志;2003年08期

6 周曉亮 ,陳軼群;血小板計(jì)數(shù)與晚期上皮性卵巢癌患者二探結(jié)果及疾病進(jìn)展的關(guān)系[J];國(guó)外醫(yī)學(xué).婦產(chǎn)科學(xué)分冊(cè);2004年06期

7 趙玲軍;術(shù)中即時(shí)化療在上皮性卵巢癌治療中的應(yīng)用[J];中國(guó)基層醫(yī)藥;2005年10期

8 Hopkins L.;Fung Kee Fung M.;王穎;;上皮性卵巢癌進(jìn)展期輔助和補(bǔ)救化療過程中患者生活質(zhì)量評(píng)估[J];世界核心醫(yī)學(xué)期刊文摘(婦產(chǎn)科學(xué)分冊(cè));2005年11期

9 王鑫;呂杰強(qiáng);朱雪瓊;;胰島素樣生長(zhǎng)因子系統(tǒng)在上皮性卵巢癌中的研究進(jìn)展[J];國(guó)外醫(yī)學(xué).婦產(chǎn)科學(xué)分冊(cè);2006年04期

10 李海玲;任慕蘭;錢惠勤;;上皮性卵巢癌血管內(nèi)皮生長(zhǎng)因子表達(dá)及微血管密度[J];江蘇醫(yī)藥;2007年01期

相關(guān)會(huì)議論文 前10條

1 程蓓;郭軼男;呂衛(wèi)國(guó);萬小云;陳亞俠;謝幸;;上皮性卵巢癌患者保留生育功能13例分析[A];第四屆長(zhǎng)三角婦產(chǎn)科學(xué)術(shù)論壇暨浙江省2009年婦產(chǎn)科學(xué)術(shù)年會(huì)論文匯編[C];2009年

2 許紅;;Ⅲ期上皮性卵巢癌的治療與預(yù)后分析[A];中國(guó)抗癌協(xié)會(huì)婦科腫瘤專業(yè)委員會(huì)第六次全國(guó)學(xué)術(shù)會(huì)議論文匯編[C];2001年

3 周慧梅;黃惠芳;潘凌亞;沈鏗;吳鳴;楊佳欣;;血清CA125值的變化對(duì)判斷上皮性卵巢癌預(yù)后的臨床價(jià)值[A];中華醫(yī)學(xué)會(huì)第九次全國(guó)婦科腫瘤學(xué)術(shù)會(huì)議論文匯編[C];2006年

4 葉海燕;陳建國(guó);徐嘉文;陳志紅;;has-miRNA let-7a在上皮性卵巢癌中的表達(dá)及其臨床意義[A];中華醫(yī)學(xué)會(huì)第十次全國(guó)婦產(chǎn)科學(xué)術(shù)會(huì)議婦科腫瘤會(huì)場(chǎng)（婦科腫瘤學(xué)組、婦科病理學(xué)組）論文匯編[C];2012年

5 謝敏;李藝;崔恒;;復(fù)發(fā)性上皮性卵巢癌的手術(shù)治療[A];中華醫(yī)學(xué)會(huì)第十次全國(guó)婦產(chǎn)科學(xué)術(shù)會(huì)議婦科腫瘤會(huì)場(chǎng)（婦科腫瘤學(xué)組、婦科病理學(xué)組）論文匯編[C];2012年

6 許紅;王中彌;左馨;;Ⅲ期上皮性卵巢癌58例臨床分析[A];中國(guó)抗癌協(xié)會(huì)婦科腫瘤專業(yè)委員會(huì)第七次全國(guó)學(xué)術(shù)會(huì)議論文匯編[C];2003年

7 郄明蓉;楊小蕓;張崇淑;;28例Ⅳ期及復(fù)發(fā)上皮性卵巢癌的治療選擇與預(yù)后分析[A];中國(guó)抗癌協(xié)會(huì)婦科腫瘤專業(yè)委員會(huì)第七次全國(guó)學(xué)術(shù)會(huì)議論文匯編[C];2003年

8 郄明蓉;鄭艾;楊小蕓;張崇淑;;28例Ⅳ期及復(fù)發(fā)上皮性卵巢癌的治療選擇與預(yù)后分析[A];第八次全國(guó)婦產(chǎn)科學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

9 郄明蓉;張崇淑;鄭艾;楊小蕓;;28例Ⅳ期及復(fù)發(fā)上皮性卵巢癌的治療選擇與預(yù)后分析[A];第八次全國(guó)婦產(chǎn)科學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

10 彭素蓉;王金華;陳小祥;;上皮性卵巢癌系統(tǒng)性腹膜后淋巴結(jié)切除術(shù)及臨床意義——附102例報(bào)告[A];江蘇省抗癌協(xié)會(huì)婦科腫瘤專業(yè)委員會(huì)第四次腫瘤學(xué)術(shù)研討會(huì)暨無錫市婦產(chǎn)科年會(huì)論文匯編[C];2005年

相關(guān)博士學(xué)位論文 前10條

1 劉東洋;FBXW7抑制上皮性卵巢癌生長(zhǎng)的作用及機(jī)制研究[D];暨南大學(xué);2017年

2 王宇;FoxM1剪接異構(gòu)體在上皮性卵巢癌中的表達(dá)及相關(guān)功能研究[D];第四軍醫(yī)大學(xué);2013年

3 金佟;CA125/T ELISA法用于CA125升高的良惡性鑒別及其臨床應(yīng)用[D];復(fù)旦大學(xué);2014年

4 嚴(yán)春曉;水通道蛋白亞型AQP5及AQP9在上皮性卵巢癌細(xì)胞增殖與遷移中的功能研究[D];浙江大學(xué);2015年

5 黃宇婷;基于定量多色熒光原位雜交技術(shù)的卵巢癌多基因拷貝數(shù)異常的研究[D];天津醫(yī)科大學(xué);2015年

6 冷若冰;Rac1在上皮性卵巢癌上皮間質(zhì)轉(zhuǎn)化中的作用及機(jī)制的初步研究[D];重慶醫(yī)科大學(xué);2015年

7 梁軍;腫瘤干細(xì)胞樣細(xì)胞在上皮性卵巢癌血管生成擬態(tài)中作用的研究[D];河北醫(yī)科大學(xué);2016年

8 胡建國(guó);MARCH7促進(jìn)上皮性卵巢癌惡性進(jìn)展及機(jī)制的研究[D];重慶醫(yī)科大學(xué);2016年

9 陸萌;FKBP14對(duì)上皮性卵巢癌細(xì)胞增殖和遷移能力的影響[D];南京醫(yī)科大學(xué);2016年

10 牛海英;PPA1通過促進(jìn)上皮—間質(zhì)轉(zhuǎn)化影響上皮性卵巢癌的轉(zhuǎn)移[D];天津醫(yī)科大學(xué);2016年

相關(guān)碩士學(xué)位論文 前10條

1 楊一鳴;血小板增多癥在上皮性卵巢癌中的診斷意義及預(yù)后評(píng)估[D];大連醫(yī)科大學(xué);2013年

2 邱章燦;Ⅲc期上皮性卵巢癌預(yù)后危險(xiǎn)因素與無進(jìn)展生存期關(guān)系探討[D];廣西醫(yī)科大學(xué);2015年

3 秦凱云;上皮性卵巢癌患者血漿化療耐藥相關(guān)蛋白質(zhì)分析及臨床意義[D];河北醫(yī)科大學(xué);2015年

4 董杰;上皮性卵巢癌中TGF-β1的表達(dá)與耐藥相關(guān)基因的關(guān)系[D];河北醫(yī)科大學(xué);2015年

5 齊新穎;LRP、GST-π表達(dá)與上皮性卵巢癌鉑類化療耐藥及預(yù)后的關(guān)系[D];河北醫(yī)科大學(xué);2015年

6 田美玲;ERCC1基因多態(tài)性及蛋白表達(dá)與上皮性卵巢癌鉑類化療敏感性及預(yù)后關(guān)系的研究[D];河北醫(yī)科大學(xué);2015年

7 賈亞靜;子宮內(nèi)膜癌、上皮性卵巢癌、早期宮頸癌預(yù)后因素分析[D];河北醫(yī)科大學(xué);2015年

8 楊晗;77例上皮性卵巢癌預(yù)后相關(guān)因素分析[D];河北醫(yī)科大學(xué);2015年

9 張根豪;阿司匹林對(duì)人上皮性卵巢癌SKOV3細(xì)胞SOX7表達(dá)和Wnt/β-catenin信號(hào)通路的影響[D];鄭州大學(xué);2015年

10 肖喜云;HER2蛋白在上皮性卵巢癌中的表達(dá)及曲妥珠單抗對(duì)卵巢癌SKOV3細(xì)胞的影響[D];河北醫(yī)科大學(xué);2015年

，

本文編號(hào)：1957957